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Abstract 
Signet ring cell carcinoma (SRCC) of the ampulla of Vater is an extremely rare tumor. Our 
case describes a 45-year-old female presenting with jaundice and pruritus. Computed to-
mography, endoscopy, and endoscopic retrograde cholangiopancreatography showed a 
tumor of the ampulla of Vater without distant metastasis. Histological biopsy confirmed a 
malignant tumor with SRCC characteristics and immunohistochemical staining revealed a 
mixed type profile (both intestinal and pancreatobiliary characteristics). A pylorus-preserving 
pancreatoduodenectomy was performed and the patient recovered without complications. 
Pathology results concluded a pT2N0 ampullary SRCC. SRCC of the ampulla of Vater is 
known to be highly malignant. After 13 months of follow-up, our patient showed no signs of 
recurrence. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
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The ampulla of Vater, also known as the hepatopancreatic duct, is formed by the union 
of the main pancreatic duct and the common bile duct. At this confluence, the epithelium of 
the biliary, pancreatic and intestinal system merges. Therefore, the ampulla of Vater is con-
sidered an interesting area regarding histopathology. Tumors in the region of the ampulla, or 
periampullary tumors, represent only a small portion of all gastrointestinal tumors. Espe-
cially true ampullary cancers are rare, with a reported population incidence of 2–6 per mil-
lion [1]. True ampullary tumors have better prognoses than other periampullary tumors in 
general, as well as a higher resectability rate [2]. Most ampullary tumors are adenocarcino-
mas with intestinal or pancreatobiliary origin, although several histopathologic variants 
have been described. One of those variants is the highly malignant signet ring cell carcinoma 
(SRCC). 
SRCC is predominantly found in gastric tumors [3], but it is also found in various tumors 
including tumors of the gastrointestinal tract, hepato-pancreato-biliary system, and urogeni-
tal system. This adenocarcinoma subtype is thought to be associated with poor prognosis in 
advanced cancer, and is thought to be less chemosensitive than non-SRCC [4]. Very few cases 
of SRCC of the ampulla of Vater are described. Less is known about the pathogenesis, treat-
ment, and outcome of this infrequent histologic subtype. Immunohistochemical staining 
might be used for further investigation of origin and characteristics of the tumor [5]. This 
report adds a case of ampullary SRCC to the few known cases. 
Case Report 
A 45-year-old female presented at the emergency department with jaundice and pruri-
tus. Apart from a hepatitis B infection in the past, the patient was healthy and her history 
and physical examination gave no further clues. Laboratory results showed high levels of 
total bilirubin (83 µmol/L at first presentation, increasing to levels above 500 µmol/L within 
2 weeks). Computed tomography showed a double duct sign (Fig. 1). Endoscopic retrograde 
cholangiopancreatography was performed, which showed a swollen ampulla of Vater suspi-
cious for malignancy. A histological biopsy showed an adenocarcinoma with the characteris-
tics of signet ring cells (Fig. 2). Immunohistochemical staining showed that the signet ring 
cells were positive for CK20, CK19, MUC-1 (weak), MUC-2, CDX-2, and DPC-4, and negative 
for CK7, ER, GCDFP, and MUC-5ac (Fig. 3). 
In the absence of metastatic disease, a pylorus-preserving pancreatoduodenectomy 
(PPPD) was performed. Histopathological findings showed an SRCC of 1.2 cm, poorly differ-
entiated, without peripancreatic invasion, lymph node involvement, angioinvasion, or peri-
neural invasion (Fig. 2, 3). The resection margins were clear of tumor cells, minimal margin 
to the tumor was 1.0 cm. Fourteen lymph nodes were identified without metastasis. The 
TNM classification according to the International Union Against Cancer (7th edition) was 
pT2N0M0. 
Our patient recovered well from surgery, and no adjuvant treatment was given. After 13 
months of follow-up, there was no evidence of recurrence. 
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This report presents a patient with an early-stage SRCC of the ampulla of Vater, with no 
signs of recurrence after a PPPD and 13 months of follow-up.  
Less is known about the pathogenesis of SRCC. Signet ring cells are round-shaped and 
contain large vacuoles. They form highly malignant and invasive tumors, with dedifferenti-
ated cells without cell-cell interaction. Fukui [6] described a mechanism of mutations in cells 
with a preexistent malignant phenotype, resulting in the formation of signet ring cells. SRCC 
is defined as the occurrence of more than 50% signet ring cells. 
Carcinoma of the ampulla of Vater accounts for 0.2% of all gastrointestinal malignancies 
and <6% of all periampullary cancers [7]. Only 37 cases of SRCC of the ampulla have been 
described so far, of which 27 in the English literature [8–11] (Table 1). The patient in the 
presented case is relatively young, and only 5 studies reported younger patients than our 
patient. The median age described in the literature is 60 years. The disease is described in 
male and female patients, although there is a slight predominance in male patients. 
Ampullary SRCC may be further divided into intestinal type (I), pancreatobiliary type 
(PB), gastric type, and mixed type [5, 12]. This classification is based on immunohistochemi-
cal staining. Expression of CK7, CK19, and MUC-1 is associated with PB-type, expression of 
CK20, MUC-2, and CDX-2 is associated with I-type, whereas co-expression of MUC-5ac and 
MUC-6 is associated with gastric type. Our case showed an immunohistochemical profile 
compatible with I-type SRCC, but it also shows the PB-type (CK19 expression and weak ex-
pression of MUC-2). This is a mixed type of SRCC, which has only been previously described 
once [5]. 
Like all periampullary tumors, surgery remains the cornerstone of treatment. In our 
case, PPPD was performed. The Dutch guideline does not recommend adjuvant chemothera-
py for ampullary tumors in general [13]. Different case reports of adding 5-fluorouracil or 
gemcitabine/cisplatin have been described, with variable results [5, 10].  
For metastatic ampullary tumors, chemotherapy is given and the subtype of the tumor 
determines the regime (PB-type vs. I-type). However, in the case of SRCC of the ampulla of 
Vater the response is unknown. The response to chemotherapy of SRCC, which is mostly 
studied in gastric, esophageal, and colorectal cancer, is thought to be less [4]. 
Median overall survival rates of 24.9 months are described with a range of 6–132 
months [8]. This compared to 37 months, which is reported for resected ampullary carcino-
ma in general [14]. Only a handful of cases report a survival of more than 5 years, although 
follow-up time is often limited at the time of publication. Lymph node invasion appears to be 
the most important prognostic factor [12, 15]. Also an I-type SRCC might have a better prog-
nosis than a PB-type SRCC [5]. Mixed type SRCC is associated with poorer prognosis, alt-
hough follow-up is too short in our case. 
In conclusion, SRCC of the ampulla of Vater is an extremely rare gastrointestinal tumor; 
this report adds a 38th case. 
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Fig. 1. CT image with adjusted plane showing a double duct sign (a) and a dilated common bile duct (b). 
 
 
 Case Rep Gastroenterol 2018;12:194–201 
DOI: 10.1159/000488903 © 2018 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/crg 







Fig. 2. a Low-power view of the ampullary tumor, infiltrating in the mucosa, submucosa, and inner muscu-
laris propria of the duodenum. HE. ×20. b High-power magnification, showing preexisting duodenal crypts 
(right) and submucosa (right) infiltrated by signet ring cells. HE. ×200. 
 
 
 Case Rep Gastroenterol 2018;12:194–201 
DOI: 10.1159/000488903 © 2018 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/crg 







Fig. 3. Immunohistochemical staining of the ampullary tumor, with benign tissue on the left border of each 
image. Positive staining for CK-19 (a), CK-20 (b), MUC-1 (c), MUC-2 (d), CDX-2 (e), DPC-4 (f), and negative 
for MUC-5ac (g). 
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Table 1. Case reports of signet ring cell carcinoma of the papilla of Vater in the English literature sorted 
chronologically 
         
         
First author Year Age,  
years 
Sex Size,  
mm 
TNM Treatment Follow-up, 
months 
Outcome 
         
         
Gardner [16] 1990 69 F 20 T3N0M0 PD 00– – 
Hara [15] 2002 68 M 15 T2N0M0 PPPD 010 Alive 
Tseng [17] 2002 47 M 20 T3N0M0 PD 006 Alive 
Eriguchi [18] 2003 83 M 15 T3N0M0 PD 018 Alive 
Li [19] 2004 56 F 15 T2N1M0 PD 012 Alive 
Ramia [20] 2004 67 F 18 T2N0M0 PD 012 Alive 
Fang [21] 2004 53 M 26 T2N0M0 PD 025 Alive 
Bloomston [22] 2005 58 F 10 T2N0M0 PD 134 Alive 
Akasu [23] 2007 43 F 20 T2N0M0 PD 090 Alive 
Gao [24] 2009 38 F 20 T3N0M0 PD 006 Alive 
Ishibashi [25] 2009 59 M 30 T3N0M0 PD 018 Died 
Gheza [26] 2011 66 M 0– – PD 008 Alive 
Paplomata [27] 2011 45 F 30 T4N1Mx PPPD adjuvant 
chemotherapy 
012 Died 
Maekawa [28] 2011 75 M 20 T3N0M0 PD 006 Died 
Lesquereux-Martínez [29] 2012 78 F 11 TxN1M0 PD adjuvant  
chemotherapy 
014 Alive 
Daoudi [30] 2012 55 M 0– T3N0M0 PD adjuvant  
chemotherapy 
008 Alive 
Acharya [31] 2013 78 F 30 T3N0M0 PD 006 Alive 
Wen [5] 2014 40 F 30 T3N0M0 PD 008 Alive 
Wen [5] 2014 64 F 65 T4NxM0 PD 076 Alive 
Wen [5] 2014 75 F 35 T4NxM0 PD 016 Died 
Wen [5] 2014 62 M 24 TxN1M0 PD 027 Died 
Wen [5] 2014 62 M 30 TxN1M0 PD 009 Died 
Wen [5] 2014 53 M 12 T3N0M0 PD 045 Alive 
Wen [5] 2014 66 F 15 T3N0M0 PD 054 Alive 
Wen [5] 2014 68 M 95 T4NxM0 PD 072 Alive 
Wakasugi [10] 2015 59 F 20 T3N1M1 PD adjuvant  
chemotherapy 
007 Alive 
Ushida [9] 2017 82 F 22 T3N0M0 PD 060 Alive 
Our case 2017 45 F 12 T2N0M0 PPPD 012 Alive 
         
         
F, female; M, male; PD, pancreatoduodenectomy; PPPD, pylorus-preserving pancreatoduodenectomy. 
 
 
 
 
 
